Clinical trial · Observational
The Performance of Multi-tracer Multimodality PET in Lymphoma
NCT05004961CI-TRIAL-00064415unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigating the performance of Multi-tracer Multimodality PET in lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Positron-Emission Tomography | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- SUVmax
- timeFrame
- 150 days
- description
- Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically diagnosed as lymphoma; * Written informed consent for receiving FAPI-04 PET examinations. * cancer planned chemotherapy or immunotherapy scheme. * expected survival ≥ 12 weeks Exclusion Criteria: * cannot lie supine for half an hour; * refuse to join the clinical researcher; * severe liver or kidney dysfunction * pregnancy or lactation
References
Publications (1)
- DERIVEDChen X, Yuan T, Wei M, Yu B, Zhou N, Zhu H, Yang Z, Wang X. Diagnostic performance of integrated whole-body 18F-FDG PET/MRI for detecting bone marrow involvement in indolent lymphoma: Comparison with 18F-FDG PET or MRI alone. Front Oncol. 2023 Mar 13;13:1136687. doi: 10.3389/fonc.2023.1136687. eCollection 2023. PMID 36994205